Organization
The Ohio State University Wexner Medical Center
19 abstracts
Abstract
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma.Org: The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, The Ohio State University James Cancer Center,
Abstract
The impacts of area-level social deprivation on overall survival in patients receiving immune-checkpoint inhibitors (ICI) treatments: A retrospective cohort study.Org: The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, Department of Biomedical Informatics, The Ohio State University College of Medicine,
Abstract
Predictors of poor response to immune-checkpoint inhibitor (ICI) treatment among patient with hepatocellular carcinoma (HCC).Org: The Ohio State University Wexner Medical Center, Columbus, OH, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Upregulation of GREB1 in colorectal cancer ovarian metastases may be a potential therapeutic target.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center, UC Irvine, The Ohio State University James Cancer Center,
Abstract
Availability of cranial prostheses for Black patients at comprehensive cancer centers.Org: The Ohio State University Wexner Medical Center, Michigan State University College of Human Medicine,
Abstract
Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).Org: The Ohio State University Wexner Medical Center, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.Org: The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University Comprehensive Canvcer Hospital, The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center,
Abstract
The Ohio State University Guardant Shield Colorectal Cancer Screening Project.Org: The Ohio State University Wexner Medical Center, Ohio State University Comprehensive Cancer Center, Ohio State University James Cancer Hospital and Solove Research Institute,
Abstract
Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.Org: The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, The Ohio State University - James Cancer Hospital, Ohio State University College of Medicine, The Ohio State University Medical Center,
Abstract
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.Org: Ohio State University Wexner Medical Center, Columbus, OH, Yale School of Medicine, Madison, CT, The Ohio State University Wexner Medical Center,
Abstract
Short-term locally advanced gastric cancer management: A cost-effectiveness analysis.Org: Rutgers- New Jersey Medical School, The Ohio State University Wexner Medical Center, Jackson Memorial Hospital, Scripps MD Anderson Cancer Center,
Abstract
Whole exome sequencing of sinonasal cancers.Org: The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital, The Ohio State University-James Cancer Hospital Solove Research Institute, The Ohio State University - James Cancer Hospital and Solove Research Institute, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center,
Abstract
Rates of hematologic toxicity in WBRT vs SRS.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, The Ohio State University Wexner Medical Center, Columbus, OH, OHB Neonatology, Ohio State University Wexner Medical Center,
Abstract
Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,
Abstract
A retrospective study of Merkel cell carcinoma treated at The Ohio State University (OSU) in the last 20 years.Org: Ohio State University Wexner Medical Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital and Solove Research Institute,